Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial.

ABSTRACT:

Background

Depressive disorders are a major global health challenge, with many individuals unresponsive to existing treatments. Novel psychedelic therapies show promise but require further research.

Objectives

This study aimed to evaluate the feasibility, safety and effectiveness of psilocybin with psychotherapeutic support for treatment-resistant depression (TRD), investigate predictors of treatment outcomes and deepen understanding of individual variability in response.

Design

Open-label, single-arm pilot trial with mixed-methods assessment.

Methods

Treatment consisted of two 25 mg psilocybin sessions, alongside three preparatory and six integration sessions. Depression severity was assessed using the self-rated Quick Inventory of Depressive Symptomatology at

SUBMITTER: Meikle S 

PROVIDER: S-EPMC12491823 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature